Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
about
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@en
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@nl
type
label
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@en
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@nl
prefLabel
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@en
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@nl
P2093
P2860
P50
P1433
P1476
Patients with chronic lymphocy ...... m CALGB 19901 and CALGB 10101.
@en
P2093
Amy S Ruppert
Bercedis Peterson
Jeffrey A Jones
Richard A Larson
Thomas S Lin
Weiqiang Zhao
P2860
P304
P356
10.3109/10428194.2013.788179
P577
2013-05-09T00:00:00Z